US FDA approves Alnylam’s Oxlumo to treat primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients

Press/Media

Period	26 Nov 2020

Media coverage

Title	US FDA approves Alnylam’s Oxlumo to treat primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients
Media name/outlet	PharmaBiz
Country/Territory	India
Date	26/11/20
URL	www.pharmabiz.com/NewsDetails.aspx?aid=133751&sid=2
Persons	Jeffrey Saland